English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/73331
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Cannabinoid system and neuroinflammation: Therapeutic perspectives in multiple sclerosis

Other TitlesEl sistema cannabinoide en situaciones de neuroinflamación: Perspectivas terapéuticas en la esclerosis múltiple
AuthorsMestre, Leyre ; Correa, Fernando Gabriel ; Docagne, Fabian ; Clemente, Diego; Ortega-Gutiérrez, S.; Arévalo, María Ángeles ; Molina-Holgado, E. ; Borrell, José ; Guaza, Carmen
Issue Date2006
PublisherViguera Editores
CitationRevista de Neurología 43: 541-548 (2006)
AbstractIntroduction. The endocannabinoid system consists of cannabinoid receptors, endogenous ligands and the enzymatic elements involved in their synthesis and breakdown. Aim. To report on currently held knowledge about the functioning of the system as a modulator of the neuroinflammatory processes associated with chronic diseases such as multiple sclerosis. Development. Cannabinoids are synthesised and released on demand and their production increases in times of neuroinflammation and neural damage. In this context then, their actions in the microglial cells and in the astrocytes are characterised by a lowered expression of inflammatory mediators and pro-inflammatory cytokines. Furthermore, cannabinoids can play a role as neuroprotectors by means of different types of mechanisms and, in experimental models of multiple sclerosis, they slow down the symptoms, reduce inflammation and can favour remyelination. Conclusions. The clinical use of cannabinoids or pharmacological agents that affect the endogenous cannabinoid system during inflammation of the central nervous system and in multiple sclerosis is currently under consideration and subject to debate. Detailed analysis of the results obtained over the past decade has made it possible to establish the existence of several mechanisms of action of cannabinoids in pathologies affecting the central nervous system that are accompanied by chronic inflammation. Likewise, they also clearly show that the cannabinoid system is an interesting proposal as a new therapeutic tool. © 2006, Revista de Neurología.
Publisher version (URL)http://doi.org/10.33588/rn.4309.2006259
URIhttp://hdl.handle.net/10261/73331
DOI10.33588/rn.4309.2006259
ISSN0210-0010
Appears in Collections:(IC) Artículos
Files in This Item:
File Description SizeFormat 
Guaza,2006,RevNeurologia,43,541-.pdf215,08 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.